First MYC inhibitor to demonstrate safety and anti-tumor activity in a phase I first-in-human clinical trial
Directed by Laura Soucek, an ICREA Research Professor, Director of VHIO's Experimental Therapeutics Program and head of our Models of Cancer Therapies Group, two decades of research aimed at combating resistance to therapy ...